Singapore Medicine Ingredients Gain Easier Access to European Union Market
Published
Active pharmaceutical ingredients (APIs) made in Singapore can now be exported to the European Union more easily and quickly. This change means that APIs used in human medicines can move through simpler and faster procedures when they are sent to EU countries.
APIs are the core chemical substances in medicines that produce the intended effect on the body. Because they are key parts of many drugs, faster export routes can help manufacturers reach overseas buyers and may reduce delays in the supply chain. The new arrangement applies specifically to APIs for human use, not to other types of products.
For Singapore, the pharmaceutical industry is an important part of the economy, and the country is home to many companies that produce medicine ingredients. Easier access to the EU, which is one of the largest markets in the world, gives local producers a clearer path to expand their business abroad. The simpler procedures may also save time and paperwork for companies that already export to Europe.
The change is a recognition of the quality of made-in-Singapore APIs. Further details about how the procedures work in practice are expected to be provided by the relevant authorities. Companies that plan to export these ingredients may wish to check the updated requirements before making new shipments.
Sources: BioSpectrum Asia
More Singapore news
- Most Singapore Tech Workers Now Based Outside the Tech Sector, Report Finds
- Korean Students Visit Singapore to Explore Tech and Industry Careers
- French AI Firm Mistral Expands Singapore Operations with New Science Hub
- Hawaii Researcher Joins Singapore Roundtable on Outer Space and Security
- Chinese Vice Premier Ding Xuexiang to Visit Singapore for Bilateral Talks
- Singaporeans Feel Left Behind as AI Push Continues
- Sokin Launches Full Operations in Singapore Under MAS Licence
- Singapore Experts Gather to Explore Better Health Data Standards